GLP-1 Receptor Agonists and Gastrointestinal Adverse Events —Reply

In Reply We thank Dr Suissa and colleagues for their critical review of our report. They question whether diabetes was adequately excluded in our study beyond the 90-day period. We agree that diabetes requires a stricter exclusion. As such, we ensured that study participants had not received an antihyperglycemic drug or a diabetes code for at least 1 year prior to cohort entry (date of the first prescription of a study drug) before the obesity restriction was applied. This detail was not included in our article due to space limitations.
Source: JAMA - Category: General Medicine Source Type: research